Summary: An antibiotic produced by Streptomyces fradiae.

Top Publications

  1. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas M. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010;16:184-6 pubmed publisher
    ..Adult ICU patients who received intravenous fosfomycin were prospectively examined to assess its safety and effectiveness as an adjunct to the antimicrobial therapy of ..
  2. Petek M, Baebler S, Kuzman D, Rotter A, Podlesek Z, Gruden K, et al. Revealing fosfomycin primary effect on Staphylococcus aureus transcriptome: modulation of cell envelope biosynthesis and phosphoenolpyruvate induced starvation. BMC Microbiol. 2010;10:159 pubmed publisher
    ..b>Fosfomycin is a potent irreversible inhibitor of MurA, an enolpyruvyl transferase that uses phosphoenolpyruvate as ..
  3. Roussos N, Karageorgopoulos D, Samonis G, Falagas M. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009;34:506-15 pubmed publisher
    ..b>Fosfomycin is an established treatment option for uncomplicated urinary tract infections...
  4. Yajima S, Hara K, Sanders J, Yin F, Ohsawa K, Wiesner J, et al. Crystallographic structures of two bisphosphonate:1-deoxyxylulose-5-phosphate reductoisomerase complexes. J Am Chem Soc. 2004;126:10824-5 pubmed
    ..The availability of these two new crystal structures opens up the possibility of the further development of bisphosphonates and related systems as DXR inhibitors and, potentially, as antiinfective agents. ..
  5. Pullukcu H, Tasbakan M, Sipahi O, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents. 2007;29:62-5 pubmed
    b>Fosfomycin tromethamine (FT) is effective in vitro in extended spectrum beta-lactamase (ESBL)-producing Escherichia coli strains. The aim of this study was to evaluate the effect of FT in the treatment of ESBL-producing E...
  6. Apisarnthanarak A, Mundy L. Successful treatment of disseminated methicillin-resistant Staphylococcus aureus with fosfomycin, cefoperazone/sulbactam and rifampin followed by fusidic acid and rifampin. Int J Infect Dis. 2007;11:283-4 pubmed
  7. Ling Y, Sahota G, Odeh S, Chan J, Araujo F, Moreno S, et al. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. J Med Chem. 2005;48:3130-40 pubmed
    ..Overall, these results indicate that alkyl bisphosphonates are promising compounds for further development as agents against Toxoplasma gondii growth, in vivo. ..
  8. Yan F, Munos J, Liu P, Liu H. Biosynthesis of fosfomycin, re-examination and re-confirmation of a unique Fe(II)- and NAD(P)H-dependent epoxidation reaction. Biochemistry. 2006;45:11473-81 pubmed
    S)-2-Hydroxypropylphosphonic acid epoxidase (HppE) catalyzes the epoxide ring closure of (S)-HPP to form fosfomycin, a clinically useful antibiotic...
  9. Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martínez Ruiz R, et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother. 2009;64:712-7 pubmed publisher
    To describe trends in fosfomycin resistance in urinary isolates of Escherichia coli producing extended-spectrum beta-lactamases (ESBLs) in relation to fosfomycin consumption and to characterize representative fosfomycin-resistant isolates...

More Information


  1. Okabayashi T, Yokota S, Yoto Y, Tsutsumi H, Fujii N. Fosfomycin suppresses chemokine induction in airway epithelial cells infected with respiratory syncytial virus. Clin Vaccine Immunol. 2009;16:859-65 pubmed publisher
    ..b>Fosfomycin (FOF) is approved as a treatment for various bacterial infectious diseases, including respiratory infectious ..
  2. Gutierrez O, Ocampo C, Aguilera J, Luna J, Sumano L. Pharmacokinetics of disodium-fosfomycin in mongrel dogs. Res Vet Sci. 2008;85:156-61 pubmed
    Pharmacokinetic variables of fosfomycin were determined after administration of buffered disodium-fosfomycin intravenously (IV), intramuscularly (IM), subcutaneously (SC) and orally (PO), in mongrel dogs, at 40 and 80 mg/kgday for three ..
  3. Sahuquillo Arce J, Colombo Gainza E, Gil Brusola A, Ortiz Estévez R, Canton E, Gobernado M. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter. 2006;19:252-7 pubmed investigate the in vitro effects of linezolid combined with five antistaphylococcal antibiotics--doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin--upon methicillin-susceptible Staphylococcus aureus (MSSA)...
  4. Endimiani A, Patel G, Hujer K, Swaminathan M, Perez F, Rice L, et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010;54:526-9 pubmed publisher
    In vitro activity of fosfomycin was evaluated against 68 bla(KPC)-possessing Klebsiella pneumoniae (KpKPC) isolates, including 23 tigecycline- and/or colistin-nonsusceptible strains...
  5. Oyakhirome S, Issifou S, Pongratz P, Barondi F, Ramharter M, Kun J, et al. Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2007;51:1869-71 pubmed
    ..These antimalarials merit further clinical exploration. ..
  6. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol. 2003;49:807-21 pubmed
    ..aureus showed significant decrease of resistance against teicoplanin, beta-lactam, bacitracin and fosfomycin but not of D-cycloserine and levofloxacin...
  7. Cheoymang A, Hudchinton D, Kioy D, Na Bangchang K. Bioassay for determination of fosmidomycin in plasma and urine: application for pharmacokinetic dose optimisation. J Microbiol Methods. 2007;69:65-9 pubmed
    ..The method appears to be robust and has been applied to a pharmacokinetic study in plasma and urinary excretion of fosmidomycin in a patient with malaria following oral doses of clindamycin at 1200 mg given every 8 h for 7 days. ..
  8. Clastre M, Goubard A, Prel A, Mincheva Z, Viaud Massuart M, Bout D, et al. The methylerythritol phosphate pathway for isoprenoid biosynthesis in coccidia: presence and sensitivity to fosmidomycin. Exp Parasitol. 2007;116:375-84 pubmed
    ..tenella and T. gondii growth in vitro. The drug was poorly effective even at high concentrations. Thus, both fosmidomycin sensitivity and isoprenoid metabolism differs substantially between apicomplexan species...
  9. Keating G. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs. 2013;73:1951-66 pubmed publisher
    b>Fosfomycin trometamol (fosfomycin tromethamine) [Monuril(®), Monurol(®), Monural(®)] is approved in numerous countries worldwide, mainly for the treatment of uncomplicated urinary tract infections (UTIs)...
  10. Mincheva Z, Courtois M, Andreu F, Rideau M, Viaud Massuard M. Fosmidomycin analogues as inhibitors of monoterpenoid indole alkaloid production in Catharanthus roseus cells. Phytochemistry. 2005;66:1797-803 pubmed
    ..Some of them have greater inhibitory effect than fosmidomycin and fully inhibit alkaloid accumulation at the concentration of 100 microM. ..
  11. McCaughey G, McKevitt M, Elborn J, Tunney M. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros. 2012;11:163-72 pubmed publisher
    ..There is a need for new antibiotics or combination of antibiotics that possess activity against increasingly resistant cystic fibrosis (CF) respiratory pathogens such as Pseudomonas aeruginosa and MRSA...
  12. Lobel B. Short term therapy for uncomplicated urinary tract infection today. Clinical outcome upholds the theories. Int J Antimicrob Agents. 2003;22 Suppl 2:85-7 pubmed
    The clinical and bacteriological activity of fosfomycin trometamol (FT) has been compared with several other antibiotics in the treatment of uncomplicated urinary tract infections...
  13. Sauermann R, Karch R, Langenberger H, Kettenbach J, Mayer Helm B, Petsch M, et al. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother. 2005;49:4448-54 pubmed
    The present study was performed to evaluate the ability of fosfomycin, a broad-spectrum antibiotic, to penetrate into abscess fluid...
  14. Eschenburg S, Priestman M, Schonbrunn E. Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. J Biol Chem. 2005;280:3757-63 pubmed
    ..template for the design of novel antibiotic drugs and is the target of the naturally occurring antibiotic fosfomycin, which covalently attaches to Cys115 in the active site of the enzyme...
  15. Al Zarouni M, Senok A, Al Zarooni N, Al Nassay F, Panigrahi D. Extended-spectrum ?-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline. Med Princ Pract. 2012;21:543-7 pubmed publisher extended-spectrum ?-Iactamase (ESBL)-producing urinary isolates with particular reference to fosfomycin, nitrofurantoin and tigecycline...
  16. Ortmann R, Wiesner J, Silber K, Klebe G, Jomaa H, Schlitzer M. Novel deoxyxylulosephosphate-reductoisomerase inhibitors: fosmidomycin derivatives with spacious acyl residues. Arch Pharm (Weinheim). 2007;340:483-90 pubmed
  17. Giessmann D, Heidler P, Haemers T, Van Calenbergh S, Reichenberg A, Jomaa H, et al. Towards new antimalarial drugs: synthesis of non-hydrolyzable phosphate mimics as feed for a predictive QSAR study on 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors. Chem Biodivers. 2008;5:643-56 pubmed publisher
    ..Synthetic access to a set of phosphonic acids with inhibitory activity (IC(50)) in the range from 1 to >30 microM vs. E. coli Dxr and 0.4 to 20 microM against P. falciparum Dxr is reported. ..
  18. Ko K, Suh J, Peck K, Lee M, Oh W, Kwon K, et al. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis. 2007;58:111-5 pubmed
    In this study, we evaluated the in vitro activity of fosfomycin and 7 other comparator agents against 307 Escherichia coli isolates including ciprofloxacin-resistant or extended-spectrum beta-lactamase (ESBL)-producing isolates...
  19. Deng L, Sundriyal S, Rubio V, Shi Z, Song Y. Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase. J Med Chem. 2009;52:6539-42 pubmed publisher
    ..4 microM. It exhibited a broad spectrum of activity against Gram-negative and -positive bacteria with minimal inhibition concentrations of 20-100 microM (or 3.7-19 microg/mL). ..
  20. McGrath J, Hammerschmidt F, Preusser W, Quinn J, Schweifer A. Studies on the biodegradation of fosfomycin: growth of Rhizobium huakuii PMY1 on possible intermediates synthesised chemically. Org Biomol Chem. 2009;7:1944-53 pubmed publisher
    The first step of the mineralisation of fosfomycin by R. huakuii PMY1 is hydrolytic ring opening with the formation of (1R,2R)-1,2-dihydroxypropylphosphonic acid...
  21. Falagas M, Roussos N, Gkegkes I, Rafailidis P, Karageorgopoulos D. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs. 2009;18:921-44 pubmed publisher
    ..We sought to evaluate fosfomycin for the treatment of infections caused by methicillin-resistant staphylococci, vancomycin-resistant enterococci, ..
  22. Rodríguez Concepción M. The MEP pathway: a new target for the development of herbicides, antibiotics and antimalarial drugs. Curr Pharm Des. 2004;10:2391-400 pubmed
    ..Current efforts should eventually contribute to an effective drug designed to fight against microbial pathogens that show resistance to currently available agents...
  23. Borrmann S, Issifou S, Esser G, Adegnika A, Ramharter M, Matsiegui P, et al. Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis. 2004;190:1534-40 pubmed
    ..Fosmidomycin-clindamycin is safe and well tolerated, and short-course regimens achieved high efficacy in children with P. falciparum malaria. Fosmidomycin-clindamycin is a promising novel treatment option for malaria. ..
  24. Alos J, Garcia Pena P, Tamayo J. [Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections]. Rev Esp Quimioter. 2007;20:211-5 pubmed
    Resistance to fosfomycin develops rapidly in experimental conditions, although despite its frequent use in UTI, resistance in E. coli, the main uropathogen, is very low (1-3%), and has remained so for many years...
  25. Ellington M, Livermore D, Pitt T, Hall L, Woodford N. Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother. 2006;58:848-52 pubmed
    b>Fosfomycin is a possible oral treatment for lower urinary tract infections caused by Escherichia coli with CTX-M extended-spectrum beta-lactamases but is vulnerable to mutational resistance. Hypermutability among natural E...
  26. Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K, Terada S, et al. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents. 2010;35:333-7 pubmed publisher
    To clarify the molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli, the murA, glpT, uhpT, uhpA, ptsI and cyaA genes were sequenced from six fosfomycin-resistant isolates...
  27. Kastoris A, Rafailidis P, Vouloumanou E, Gkegkes I, Falagas M. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol. 2010;66:359-68 pubmed publisher
    ..b>Fosfomycin shows no cross-resistance to other antibiotic classes...
  28. Engel H, Gutiérrez Fernández J, Flückiger C, Martinez Ripoll M, Mühlemann K, Hermoso J, et al. Heteroresistance to fosfomycin is predominant in Streptococcus pneumoniae and depends on the murA1 gene. Antimicrob Agents Chemother. 2013;57:2801-8 pubmed publisher
    b>Fosfomycin targets the first step of peptidoglycan biosynthesis in Streptococcus pneumoniae catalyzed by UDP-N-acetylglucosamine enolpyruvyltransferase (MurA1). We investigated whether heteroresistance to fosfomycin occurs in S...
  29. Andaloussi M, Henriksson L, Wieckowska A, Lindh M, Björkelid C, Larsson A, et al. Design, synthesis, and X-ray crystallographic studies of ?-aryl substituted fosmidomycin analogues as inhibitors of Mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate reductoisomerase. J Med Chem. 2011;54:4964-76 pubmed publisher
  30. Fokin A, Yurchenko A, Rodionov V, Gunchenko P, Yurchenko R, Reichenberg A, et al. Synthesis of the antimalarial drug FR900098 utilizing the nitroso-ene reaction. Org Lett. 2007;9:4379-82 pubmed
    ..The utilization of dibenzyl allylphosphonate as the starting compound allows one-step hydrogenation with dealkylation, which simplifies the preparative scheme further. ..
  31. Kurz T, Behrendt C, Pein M, Kaula U, Bergmann B, Walter R. gamma-Substituted bis(pivaloyloxymethyl)ester analogues of fosmidomycin and FR900098. Arch Pharm (Weinheim). 2007;340:661-6 pubmed
  32. Yoon H, Lee S, Mikami B, Park H, Yoo J, Suh S. Crystal structure of UDP-N-acetylglucosamine enolpyruvyl transferase from Haemophilus influenzae in complex with UDP-N-acetylglucosamine and fosfomycin. Proteins. 2008;71:1032-7 pubmed publisher
  33. Ishizaka K, Kobayashi S, Machida T, Yoshida K. Randomized prospective comparison of fosfomycin and cefotiam for prevention of postoperative infection following urological surgery. J Infect Chemother. 2007;13:324-31 pubmed
    A randomized study design was used to compare the efficacy of cefotiam (CTM) and fosfomycin (FOM) for preventing infection associated with urologic surgery...
  34. Knottnerus B, Nys S, ter Riet G, Donker G, Geerlings S, Stobberingh E. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?. J Antimicrob Chemother. 2008;62:356-9 pubmed publisher
    ..The third choice is fosfomycin tromethamine for which no current resistance data from The Netherlands are available...
  35. Sakamoto Y, Furukawa S, Ogihara H, Yamasaki M. Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli. Biosci Biotechnol Biochem. 2003;67:2030-3 pubmed
    ..were found to be resistant to fosmidomycin, a specific inhibitor of the non-mevalonate pathway, just like to fosfomycin. E. coli glpT mutants were resistant to fosfomycin and also to fosmidomycin...
  36. Liu H, Lin H, Lin Y, Yu S, Wu W, Lee Y. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect. 2011;44:364-8 pubmed publisher
    ..The role of fosfomycin in the era of growing bacteria resistance has been widely discussed recently...
  37. Ortmann R, Wiesner J, Reichenberg A, Henschker D, Beck E, Jomaa H, et al. Alkoxycarbonyloxyethyl ester prodrugs of FR900098 with improved in vivo antimalarial activity. Arch Pharm (Weinheim). 2005;338:305-14 pubmed
    ..Prodrugs with increased oral activity in mice infected with the rodent malaria parasite Plasmodium vinckei were obtained by masking the phosphonate moiety of FR900098 as alkoxycarbonyloxyethyl esters. ..
  38. Na Bangchang K, Ruengweerayut R, Karbwang J, Chauemung A, Hutchinson D. Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria. Malar J. 2007;6:70 pubmed
    ..falciparum. ..
  39. Garrigós C, Murillo O, Lora Tamayo J, Verdaguer R, Tubau F, Cabellos C, et al. Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013;57:606-10 pubmed publisher
    The efficacy of daptomycin, imipenem, or rifampin with fosfomycin was evaluated and compared with that of daptomycin-rifampin in a tissue cage model infection caused by methicillin-resistant Staphylococcus aureus (MRSA)...
  40. Devreux V, Wiesner J, Jomaa H, Rozenski J, Van der Eycken J, Van Calenbergh S. Divergent strategy for the synthesis of alpha-aryl-substituted fosmidomycin analogues. J Org Chem. 2007;72:3783-9 pubmed
    ..An alpha-(4-cyanophenyl)fosmidomycin analogue emerged as the most potent analogue in the present series. Its antimalarial activity clearly surpasses that of the reference compound fosmidomycin. ..
  41. Andaloussi M, Lindh M, Björkelid C, Suresh S, Wieckowska A, Iyer H, et al. Substitution of the phosphonic acid and hydroxamic acid functionalities of the DXR inhibitor FR900098: an attempt to improve the activity against Mycobacterium tuberculosis. Bioorg Med Chem Lett. 2011;21:5403-7 pubmed publisher
    ..The best inhibitors provided IC(50) values in the micromolar range, with a best value of 41 ?M. ..
  42. Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Lagler H, et al. Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Antimicrob Agents Chemother. 2011;55:4999-5003 pubmed publisher
    The in vivo activities of daptomycin, fosfomycin, and a combination of both antibiotics against a clinical isolate of methicillin-resistant Staphylococcus aureus (daptomycin MIC, 0.25 ?g/ml; fosfomycin MIC, 0...
  43. Rodríguez Rojas A, Maciá M, Couce A, Gomez C, Castañeda García A, Oliver A, et al. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS ONE. 2010;5:e10193 pubmed publisher
    b>Fosfomycin is a cell wall inhibitor used efficiently to treat uncomplicated urinary tract and gastrointestinal infections...
  44. Jawaid S, Seidle H, Zhou W, Abdirahman H, Abadeer M, Hix J, et al. Kinetic characterization and phosphoregulation of the Francisella tularensis 1-deoxy-D-xylulose 5-phosphate reductoisomerase (MEP synthase). PLoS ONE. 2009;4:e8288 pubmed publisher
    ..tularensis MEP pathway. Overall, our study suggests that MEP synthase is an excellent target for the development of novel antibiotics against F. tularensis...
  45. Haemers T, Wiesner J, Van Poecke S, Goeman J, Henschker D, Beck E, et al. Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors. Bioorg Med Chem Lett. 2006;16:1888-91 pubmed
    ..It is approximately three times more potent in inhibiting the growth of P. falciparum than FR900098, the most potent representative of this class reported so far. ..
  46. MacLeod D, Barker L, Sutherland J, Moss S, Gurgel J, Kenney T, et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother. 2009;64:829-36 pubmed publisher
    To compare the in vitro and in vivo activities of a 4:1 (w/w) fosfomycin/tobramycin combination (FTI) with those of fosfomycin and tobramycin alone against cystic fibrosis (CF) and non-CF bronchiectasis pathogens...
  47. Gattringer R, Meyer B, Heinz G, Guttmann C, Zeitlinger M, Joukhadar C, et al. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. J Antimicrob Chemother. 2006;58:367-71 pubmed
    Dosage recommendations for fosfomycin are available for haemodialysed patients but there are no data for patients undergoing continuous renal replacement therapy...
  48. McGrath J, Hammerschmidt F, Kählig H, Wuggenig F, Lamprecht G, Quinn J. Studies on the biodegradation of fosfomycin: synthesis of 13C-labeled intermediates, feeding experiments with Rhizobium huakuii PMY1, and isolation of labeled amino acids from cell mass by HPLC. Chemistry. 2011;17:13341-8 pubmed publisher
    ..It was found that the carbon atoms of the respective carboxyl groups were highly (13)C-labeled (up to 65?%). Hydroxyacetone is therefore considered an obligatory intermediate of the biodegradation of fosfomycin by R. huakuii PMY1.
  49. Cai Y, Fan Y, Wang R, An M, Liang B. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model. J Antimicrob Chemother. 2009;64:563-6 pubmed publisher
    ..and in vivo efficacy of aminoglycosides against Pseudomonas aeruginosa, either alone or in combination with fosfomycin. Using an in vitro study to assess inhibition of the growth of P...
  50. Raz R. Fosfomycin: an old--new antibiotic. Clin Microbiol Infect. 2012;18:4-7 pubmed publisher
    b>Fosfomycin is a broad-spectrum antibiotic discovered in Spain in 1969. It has bactericidal activity against a wide range of bacteria, including gram-negative micro-organisms and some gram-positive bacteria, such as staphylococci...
  51. Yokota S, Okabayashi T, Yoto Y, Hori T, Tsutsumi H, Fujii N. Fosfomycin suppresses RS-virus-induced Streptococcus pneumoniae and Haemophilus influenzae adhesion to respiratory epithelial cells via the platelet-activating factor receptor. FEMS Microbiol Lett. 2010;310:84-90 pubmed publisher
    ..b>Fosfomycin, an antimicrobial agent, significantly suppressed PAF receptor induction by RSV infection at the mRNA and cell ..
  52. Chen L, Huang C, Kuo S, Hsiao C, Lin M, Wang F, et al. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect Dis. 2011;11:152 pubmed publisher surgical removal of the ICD device and combination antimicrobial therapy with high-dose daptomycin and fosfomycin. Surgical removal of intracardiac devices remains an important adjunctive measure in the treatment of ..
  53. Nakazawa H, Kikuchi Y, Honda T, Isago T, Nozaki M. Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin. J Infect Chemother. 2003;9:304-9 pubmed
    The present study was designed to evaluate the efficacy of fosfomycin used in combination with drugs that were found to be less effective against methicillin-resistant Staphylococcus aureus (MRSA)...
  54. Nabeth P, Perrier Gros Claude J, Juergens Behr A, Dromigny J. In vitro susceptibility of quinolone-resistant Enterobacteriaceae uropathogens to fosfomycin trometamol, in Dakar, Senegal. Scand J Infect Dis. 2005;37:497-9 pubmed
    We conducted a study in order to confirm the eligibility of fosfomycin trometamol as an alternative treatment to quinolones for urinary tract infections...
  55. Zinglé C, Kuntz L, Tritsch D, Grosdemange Billiard C, Rohmer M. Isoprenoid biosynthesis via the methylerythritol phosphate pathway: structural variations around phosphonate anchor and spacer of fosmidomycin, a potent inhibitor of deoxyxylulose phosphate reductoisomerase. J Org Chem. 2010;75:3203-7 pubmed publisher
    ..e., sulfonate or carboxylate functionalities. The potential of the synthesized analogues to inhibit the E. coli DXR was evaluated. ..
  56. Verbrugghen T, Cos P, Maes L, Van Calenbergh S. Synthesis and evaluation of alpha-halogenated analogues of 3-(acetylhydroxyamino)propylphosphonic acid (FR900098) as antimalarials. J Med Chem. 2010;53:5342-6 pubmed publisher
    ..These analogues were evaluated for antimalarial potential in vitro against Plasmodium falciparum and in vivo in the P. berghei mouse model. All three analogues showed higher in vitro and/or in vivo potency than the reference compounds. ..
  57. Senol S, Tasbakan M, Pullukcu H, Sipahi O, Sipahi H, Yamazhan T, et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother. 2010;22:355-7 pubmed
    The aim of this observational prospective study was to compare the effect of fosfomycin tromethanol (FT) and carbapenems (meropenem or imipenem cilastatin) in the treatment of extended-spectrum beta-lactamase (ESBL)-producing Escherichia ..
  58. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43:52-9 pubmed publisher
    b>Fosfomycin is active in vitro against extensively drug-resistant (XDR) and pandrug-resistant (PDR) Pseudomonas aeruginosa and Klebsiella pneumoniae carbapenemase-producing strains; however, the in vivo effectiveness against such pathogens ..
  59. Mirakhur A, Gallagher M, Ledson M, Hart C, Walshaw M. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros. 2003;2:19-24 pubmed
    ..The antibiotic Fosfomycin has a unique mode of action against this organism, and may protect against aminoglycoside mediated renal and ..
  60. Borrmann S, Adegnika A, Matsiegui P, Issifou S, Schindler A, Mawili Mboumba D, et al. Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis. 2004;189:901-8 pubmed
    ..The combination of fosmidomycin and clindamycin is well tolerated and superior to either agent on its own with respect to the rapid and radical clearance of P. falciparum infections in African children. ..
  61. Munos J, Moon S, Mansoorabadi S, Chang W, Hong L, Yan F, et al. Purification and characterization of the epoxidase catalyzing the formation of fosfomycin from Pseudomonas syringae. Biochemistry. 2008;47:8726-35 pubmed publisher
    The final step in the biosynthesis of fosfomycin in Streptomyces wedmorensis is catalyzed by ( S)-2-hydroxypropylphosphonic acid (HPP) epoxidase ( Sw-HppE)...
  62. Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend?. Eur J Clin Microbiol Infect Dis. 2010;29:127-42 pubmed publisher
    b>Fosfomycin (FOM) is an antibiotic which has varying application indications across the globe...
  63. Dhiman R, Schaeffer M, Bailey A, Testa C, Scherman H, Crick D. 1-Deoxy-D-xylulose 5-phosphate reductoisomerase (IspC) from Mycobacterium tuberculosis: towards understanding mycobacterial resistance to fosmidomycin. J Bacteriol. 2005;187:8395-402 pubmed
    ..Thus, M. tuberculosis resistance to fosmidomycin is not due to intrinsic properties of Rv2870c, and the enzyme appears to be a valid drug target in this pathogen. ..
  64. Marchese A, Bozzolasco M, Gualco L, Debbia E, Schito G, Schito A. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int J Antimicrob Agents. 2003;22 Suppl 2:95-100 pubmed
    Four slime-producing uropathogenic Escherichia coli strains were used to investigate the activity of fosfomycin and N-acetylcysteine (NAC) against biofilms developed on 96-well polystyrene tissue culture plates...
  65. Honderlick P, Cahen P, Gravisse J, Vignon D. [Uncomplicated urinary tract infections, what about fosfomycin and nitrofurantoin in 2006?]. Pathol Biol (Paris). 2006;54:462-6 pubmed
    ..A total of 19 618 bacteria were studied, fosfomycin, fluoroquinolones, nitrofurantoin were in vitro the most potent drugs with more than 80% of susceptibility...
  66. Rodríguez Concepción M, Forés O, Martinez Garcia J, Gonzalez V, Phillips M, Ferrer A, et al. Distinct light-mediated pathways regulate the biosynthesis and exchange of isoprenoid precursors during Arabidopsis seedling development. Plant Cell. 2004;16:144-56 pubmed
  67. Uh E, Jackson E, San Jose G, Maddox M, Lee R, Lee R, et al. Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. Bioorg Med Chem Lett. 2011;21:6973-6 pubmed publisher
    ..Our results show that this strategy can be an effective way for improving whole cell activity of NMP inhibitors. ..
  68. Lu C, Liu C, Huang Y, Liao C, Teng L, Turnidge J, et al. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother. 2011;55:4295-301 pubmed publisher
    We studied the antimicrobial activity of fosfomycin against 960 strains of commonly encountered bacteria associated with urinary tract infection using standard agar dilution and disk diffusion methods...
  69. Henriksson L, Unge T, Carlsson J, Aqvist J, Mowbray S, Jones T. Structures of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase provide new insights into catalysis. J Biol Chem. 2007;282:19905-16 pubmed
    ..The conformation of fosmidomycin bound to the metal ion is different from that reported in a previously published structure and indicates that a rearrangement of the intermediate is not required during catalysis. ..
  70. Cassera M, Merino E, Peres V, Kimura E, Wunderlich G, Katzin A. Effect of fosmidomycin on metabolic and transcript profiles of the methylerythritol phosphate pathway in Plasmodium falciparum. Mem Inst Oswaldo Cruz. 2007;102:377-83 pubmed
    ..This is the first study that compares the effect of fosmidomycin on the metabolic and transcript profiles in P. falciparum, which has only the MEP pathway for isoprenoid biosynthesis. ..
  71. Ortmann R, Wiesner J, Reichenberg A, Henschker D, Beck E, Jomaa H, et al. Acyloxyalkyl ester prodrugs of FR900098 with improved in vivo anti-malarial activity. Bioorg Med Chem Lett. 2003;13:2163-6 pubmed
    ..The most successful compound demonstrated 2-fold increased activity in mice infected with the rodent malaria parasite Plasmodium vinckei. ..
  72. Blacky A, Makristathis A, Apfalter P, Willinger B, Rotter M, Hirschl A. In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori compared with combined clarithromycin and metronidazole. Eur J Clin Microbiol Infect Dis. 2005;24:276-9 pubmed
    In order to evaluate the suitability of fosfomycin in combination with other agents for the treatment of Helicobacter pylori infections, the susceptibility profiles of 65 H...
  73. Shinagawa N, Mizuno I, Fukui T, Takeyama H, Yasuda A, Matsumoto K, et al. [Prophylactic effect of fosfomycin on postoperative infection in gastroenterological surgery]. Jpn J Antibiot. 2006;59:417-27 pubmed
    b>Fosfomycin (FOM), a drug with unique mechanism of action against bacteria, was prospectively compared with cefmetazole (CMZ) and flomoxef (FMOX) to assess its effectiveness in preventing postoperative infections after upper ..
  74. Castañeda García A, Rodríguez Rojas A, Guelfo J, Blazquez J. The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J Bacteriol. 2009;191:6968-74 pubmed publisher
    b>Fosfomycin is transported into Escherichia coli via both glycerol-3-phosphate (GlpT) and a hexose phosphate transporter (UhpT). Consequently, the inactivation of either glpT or uhpT confers increased fosfomycin resistance in this species...
  75. Soraci A, Perez D, Martinez G, Dieguez S, Tapia M, Amanto F, et al. Disodium-fosfomycin pharmacokinetics and bioavailability in post weaning piglets. Res Vet Sci. 2011;90:498-502 pubmed publisher
    Disodium-fosfomycin pharmacokinetics has been studied in different species after oral, intravenous, intramuscular and subcutaneous administration...
  76. Falagas M, Grammatikos A, Michalopoulos A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther. 2008;6:593-600 pubmed publisher
    ..A number of old antibiotic compounds, such as polymyxins, fosfomycin, fusidic acid, cotrimoxazole, aminoglycosides and chloramphenicol, are re-emerging as valuable alternatives for ..
  77. Falagas M, Vouloumanou E, Togias A, Karadima M, Kapaskelis A, Rafailidis P, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65:1862-77 pubmed publisher
    ..Cystitis is a common infection. The alarmingly high resistance rates exhibited by contemporary uropathogens necessitate the re-evaluation of old antibiotics...
  78. Liu P, Liu A, Yan F, Wolfe M, Lipscomb J, Liu H. Biochemical and spectroscopic studies on (S)-2-hydroxypropylphosphonic acid epoxidase: a novel mononuclear non-heme iron enzyme. Biochemistry. 2003;42:11577-86 pubmed
    The last step of the biosynthesis of fosfomycin, a clinically useful antibiotic, is the conversion of (S)-2-hydroxypropylphosphonic acid (HPP) to fosfomycin...
  79. Souli M, Galani I, Boukovalas S, Gourgoulis M, Chryssouli Z, Kanellakopoulou K, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother. 2011;55:2395-7 pubmed publisher
    Using time-kill methodology, we investigated the interactions of fosfomycin with meropenem or colistin or gentamicin against 17 genetically distinct Klebsiella pneumoniae clinical isolates carrying blaKPC-2...
  80. Mikuniya T, Kato Y, Kariyama R, Monden K, Hikida M, Kumon H. Synergistic effect of fosfomycin and fluoroquinolones against Pseudomonas aeruginosa growing in a biofilm. Acta Med Okayama. 2005;59:209-16 pubmed
    ..In this study, we examined the combined effect of fosfomycin and ulifloxacin against Pseudomonas aeruginosa (P...
  81. Sahni R, Balaji V, Varghese R, John J, Tansarli G, Falagas M. Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study. Future Microbiol. 2013;8:675-80 pubmed publisher
    The aim was to evaluate the in vitro activity of fosfomycin against common uropathogens in a fosfomycin-naive population in India...
  82. Falagas M, Maraki S, Karageorgopoulos D, Kastoris A, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35:240-3 pubmed publisher
    ..We sought to evaluate the in vitro antimicrobial activity of fosfomycin against multidrug-resistant (MDR) Enterobacteriaceae isolates...
  83. de Cueto M, Lopez L, Hernandez J, Morillo C, Pascual A. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother. 2006;50:368-70 pubmed
    ..of 428 extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin. Fosfomycin showed very high activity against all ESBL-producing strains...
  84. Neuner E, Sekeres J, Hall G, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012;56:5744-8 pubmed publisher
    b>Fosfomycin has shown promising in vitro activity against multidrug-resistant (MDR) urinary pathogens; however, clinical data are lacking...
  85. Falagas M, Kastoris A, Karageorgopoulos D, Rafailidis P. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents. 2009;34:111-20 pubmed publisher
    ..This mandates the re-evaluation of already existing antibiotics such as fosfomycin. We systematically reviewed the literature to assess the clinical and microbiological effectiveness of ..
  86. Nilsson A, Berg O, Aspevall O, Kahlmeter G, Andersson D. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother. 2003;47:2850-8 pubmed
    b>Fosfomycin is a cell wall inhibitor used mainly for the treatment of uncomplicated lower urinary tract infections...
  87. Rigsby R, Rife C, Fillgrove K, Newcomer M, Armstrong R. Phosphonoformate: a minimal transition state analogue inhibitor of the fosfomycin resistance protein, FosA. Biochemistry. 2004;43:13666-73 pubmed publisher
    b>Fosfomycin [(1R,2S)-epoxypropylphosphonic acid] is a simple phosphonate found to have antibacterial activity against both Gram-positive and Gram-negative microorganisms...
  88. Dharia N, Sidhu A, Cassera M, Westenberger S, Bopp S, Eastman R, et al. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol. 2009;10:R21 pubmed publisher
    ..The ability to define comprehensively genetic variability in P. falciparum with a single overnight hybridization creates new opportunities to study parasite evolution and improve the treatment and control of malaria. ..
  89. Xu H, Miao V, Kwong W, Xia R, Davies J. Identification of a novel fosfomycin resistance gene (fosA2) in Enterobacter cloacae from the Salmon River, Canada. Lett Appl Microbiol. 2011;52:427-9 pubmed publisher
    To investigate the occurrence of fosfomycin-resistant (fos(R) ) bacteria in aquatic environments.
  90. Karageorgopoulos D, Wang R, Yu X, Falagas M. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2012;67:255-68 pubmed publisher
    b>Fosfomycin has attracted renewed interest for the treatment of lower urinary tract and even systemic infections caused by Gram-negative pathogens with resistance to traditionally used agents...
  91. Woodyer R, Shao Z, Thomas P, Kelleher N, Blodgett J, Metcalf W, et al. Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster. Chem Biol. 2006;13:1171-82 pubmed
    b>Fosfomycin is a clinically utilized, highly effective antibiotic, which is active against methicillin- and vancomycin-resistant pathogens...